Used in targeted cancer therapy, particularly in the treatment of solid tumors such as non-small cell lung cancer and ovarian cancer. It binds specifically to PTK7 (protein tyrosine kinase 7), a receptor overexpressed in various cancer cells, enabling selective delivery of cytotoxic agents when conjugated as an antibody-drug conjugate (ADC). This targeted approach helps minimize damage to healthy cells, improving therapeutic efficacy and reducing side effects. It is also employed in research settings to study PTK7 expression and its role in tumor progression.